Novacea halts Phase III trial of prostate cancer drug on imbalance of deaths |
|
|
|
Published
:
Mon, 05 Nov 2007 12:57
|
NEW YORK (Thomson Financial) - Novacea Inc. Monday said it had halted the Phase III clinical trial of its drug Asentar, an investigational prostate cancer therapy.The San Francisco-based pharmaceutical company said there was an 'imbalance of deaths' between the two treatment arms. Novacea, along with its partner Schering-Plough, plans to analyze the data in order to understand why there was a higher death rate in the group being treated with Asentar and Taxotere.The companies said they wouldn't end their development alliance.Shares of Novacea closed Friday at $7.19.Schering-Plough is a pharmaceutical based in Kenilworth, N.J. Its stock closed Friday at $29.96.Ryan Vlastelicarv/pcCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
Print this Story
BioXell to commence phase IIa trial on Elocalcitol's effects on male infertility 